Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (441-450 of 504) with videos related to

Pageof 51
Sort By:
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood|February 26, 2015
Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemiaSaradhi Mallampati, Xiaohong Leng, Haiqing Ma, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Bcl-B expression in human epithelial and nonepithelial malignanciesMaryla Krajewska, Shinichi Kitada, Jane N Winter, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Science Signaling|February 18, 2016
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignanciesJo Ishizawa, Kensuke Kojima, Dhruv Chachad, et al.
American Journal of Hematology|May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Blood|March 14, 2007
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaChiara Gregorj, Maria R Ricciardi, Maria T Petrucci, et al.
Pageof 51

Showing results (441-450 of 504) with videos related to

Sort By:
Pageof 51
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood|February 26, 2015
Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemiaSaradhi Mallampati, Xiaohong Leng, Haiqing Ma, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Bcl-B expression in human epithelial and nonepithelial malignanciesMaryla Krajewska, Shinichi Kitada, Jane N Winter, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Science Signaling|February 18, 2016
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignanciesJo Ishizawa, Kensuke Kojima, Dhruv Chachad, et al.
American Journal of Hematology|May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemiaCourtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Blood|March 14, 2007
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaChiara Gregorj, Maria R Ricciardi, Maria T Petrucci, et al.
Pageof 51